Publications by authors named "B Korge"
Introduction: Certolizumab pegol (CZP) is an anti-tumor necrosis factor alpha (TNFα) approved for the treatment of moderate to severe plaque psoriasis (PSO). However, data on its real-world use is currently limited. The objective of this study was to describe the 1-year real-world effectiveness of CZP, its impact on health-related quality of life (HRQoL), and safety outcomes in patients with moderate to severe PSO in multi-country settings.
View Article and Find Full Text PDFArticle Synopsis
- The PERSIST study examined the effectiveness and safety of guselkumab and ustekinumab in adult patients with moderate-to-severe plaque psoriasis over 104 weeks.
- Both treatments resulted in significant improvements in disease activity and quality-of-life outcomes, with 64.7% of guselkumab recipients achieving a PASI 90 response compared to 54.6% for ustekinumab.
- Although both treatments were effective, guselkumab showed higher response rates, especially in biologic-naïve patients, indicating a potential preference for its use in certain cases.
Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT.
J Eur Acad Dermatol Venereol
January 2023
Background: Plaque psoriasis is a chronic inflammatory disorder affecting the skin and impacting quality of life. Tildrakizumab (TIL) is an IL-23 inhibitor licensed for moderate-to-severe plaque psoriasis. Regulatory approval of medicinal products is based on safety and efficacy data from randomized controlled trials (RCTs) which impose stringent selection criteria.
View Article and Find Full Text PDFBackground: PERSIST was a prospective, non-interventional, long-term, German multicentre study of patients with moderate-to-severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23, in a real-world setting.
Objectives: Evaluation of the efficacy and safety of guselkumab, and its effect on health-related quality of life (HRQoL), in patients with moderate-to-severe psoriasis who have received 52 weeks of treatment.
Methods: Patients (≥18 years old) were prescribed guselkumab as per routine clinical practice.